The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy

Gkika, Eleni; Bettinger, Dominik; Krafft, L.; Schultheiß, Michael; Neeff, Hannes; Maruschke, Lars; Schulenburg, Michaela; Adebahr, S.; Kirste, Simon; Nestle, Ursula; Thimme, Robert; Grosu, Anca‐Ligia; Brunner, Thomas

doi:10.1007/s00066-017-1256-0

Cited by 23 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since then, intracranial stereotactic radiosurgery (SRS, 1 treatment session) and intracranial fractionated stereotactic radiotherapy (FSRT, 2-12 treatment sessions) have become an integral part in the treatment of single and multiple brain metastases, also in combination with immune-and targeted-therapies [8], benign tumors (e.g., meningioma, acoustic neuromas, or pituitary adenomas) [9], vascular malformations and functional disorders (e.g., trigeminal neuralgia) [10], among others. With recent advances in image guidance and motion management for organ and target movements (e.g., due to respiration), extracranial stereotactic body radiotherapy (SBRT, 1-12 treatment sessions) has also become a standard treatment option for many indications including primary lung, liver, pancreas, kidney, and prostate cancer [11][12][13], as well as oligometastases in lung, liver, bone, and abdominal localization [14][15][16]. Due to rapid technical development of this method in the past 2 decades, SBRT now allows a highly precise dose deposition in any target in the body with steep dose gradients to surrounding healthy organs.…”

Section: Radiosurgery and Stereotactic Body Radiotherapymentioning

confidence: 99%

Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA)

et al. 2020

View full text Add to dashboard Cite

Background Single-session high-dose stereotactic radiotherapy (radiosurgery) is a new treatment option for otherwise untreatable patients suffering from refractory ventricular tachycardia (VT). In the initial single-center case studies and feasibility trials, cardiac radiosurgery has led to significant reductions of VT burden with limited toxicities. However, the full safety profile remains largely unknown. Methods/design In this multi-center, multi-platform clinical feasibility trial which we plan is to assess the initial safety profile of radiosurgery for ventricular tachycardia (RAVENTA). High-precision image-guided single-session radiosurgery with 25 Gy will be delivered to the VT substrate determined by high-definition endocardial electrophysiological mapping. The primary endpoint is safety in terms of successful dose delivery without severe treatment-related side effects in the first Jürgen Dunst and Hendrik Bonnemeier have equally contributed to this work. This is the first publication for the RAVENTA study.

show abstract

Section: Radiosurgery and Stereotactic Body Radiotherapymentioning

confidence: 99%

Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Chronic inflammation is generally understood to play a critical role in tumor initiation and promotion [ 9 ]. Therefore, an inflammation-based index using serum c-reactive protein (CRP) and albumin values was shown to correlate with survival in patients with hepatocellular carcinoma undergoing stereotactic body radiotherapy [ 10 ]. Moreover, inflammatory reactions leading to metabolic alterations are strongly linked with muscle wasting, a key symptom of cancer cachexia [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

et al. 2019

View full text Add to dashboard Cite

Background Deficiency in butyrylcholinesterase (BChE), a condition commonly noticed in liver damage, inflammation, and malnutrition, has previously been associated with impaired prognosis in different malignancies. The aim of the present study was to investigate the value of pretreatment serum BChE levels as a prognostic biomarker in patients with cervical cancer treated with primary (chemotherapy-[chemo-])radiation therapy. Methods We retrospectively evaluated data of a consecutive series of patients with cervical cancer treated with primary (chemo-)radiation therapy between 1998 and 2015. Pretreatment serum BChE levels were correlated with clinico-pathological parameters and response to treatment. Uni- and multivariate survival analyses were performed to assess the association between decreased serum BChE levels and progression-free (PFS), cancer-specific (CSS), and overall survival (OS). Results A total of 356 patients were eligible for inclusion into the present study. The median (IQR) pretreatment serum BChE level was 6180 (4990–7710) IU/l. Lower serum BChE levels were associated with lower BMI ( p < 0.001), advanced tumor stage ( p = 0.04), poor treatment response ( p = 0.002), the occurrence of disease recurrence ( p = 0.003), and the risk of death ( p < 0.001). In uni- and multivariate analyses, low pretreatment serum BChE levels were independently associated with shorter PFS (HR 1.8 [1.2–2.6]; p = 0.002), CSS (HR 2.2 [1.4–3.5], p < 0.001), and OS (HR 2.0 [1.4–2.9]; p < 0.001). Conclusions Low pretreatment serum BChE levels are associated with advanced tumor stage and poor response to treatment, and serve as an independent prognostic biomarker for shorter PFS, CSS, and OS in patients with cervical cancer treated with primary (chemo-)radiation therapy.

show abstract

“…When it comes to a healthy liver, 80% of the organ can be removed. Although the whole liver exhibits a low radiation tolerance, potentially leading to the serious condition of radiotherapy-induced liver disease (RILD) [43][44][45][46][47][48][49], the regenerative potential and the parallel radiobiological character of the liver allows for application of high doses to a defined volume without compromising liver function [50].…”

Section: Target Volume Definition: Automatic Segmentation Of Target Vmentioning

confidence: 99%

Radiomics for liver tumours

et al. 2020

View full text Add to dashboard Cite

Current research, especially in oncology, increasingly focuses on the integration of quantitative, multiparametric and functional imaging data. In this fast-growing field of research, radiomics may allow for a more sophisticated analysis of imaging data, far beyond the qualitative evaluation of visible tissue changes. Through use of quantitative imaging data, more tailored and tumour-specific diagnostic work-up and individualized treatment concepts may be applied for oncologic patients in the future. This is of special importance in cross-sectional disciplines such as radiology and radiation oncology, with already high and still further increasing use of imaging data in daily clinical practice. Liver targets are generally treated with stereotactic body radiotherapy (SBRT), allowing for local dose escalation while preserving surrounding normal tissue. With the introduction of online target surveillance with implanted markers, 3D-ultrasound on conventional linacs and hybrid magnetic resonance imaging (MRI)-linear accelerators, individualized adaptive radiotherapy is heading towards realization. The use of big data such as radiomics and the integration of artificial intelligence techniques have the potential to further improve image-based treatment planning and structured follow-up, with outcome/toxicity prediction and immediate detection of (oligo)progression. The scope of current research in this innovative field is to identify and critically discuss possible application forms of radiomics, which is why this review tries to summarize current knowledge about interdisciplinary integration of radiomics in oncologic patients, with a focus on investigations of radiotherapy in patients with liver cancer or oligometastases including multiparametric, quantitative data into (radio)-oncologic workflow from disease diagnosis, treatment planning, delivery and patient follow-up.

show abstract

The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy

Abstract: In this analysis, a higher ALBI grade as well as a higher CP were predictors of higher incidence of toxicity, whereas a lower IBI during treatment correlated with a better OS. These results should be further evaluated in prospective studies.

Cited by 23 publications

References 29 publications

Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA)

Radiosurgery for ventricular tachycardia: preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA)

The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy

Radiomics for liver tumours

Contact Info

Product

Resources

About